ClinicalTrials.gg
CompletedNCT03438279Updated Feb 19, 2018

Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy

An observational study in Melanoma, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-19.

Sponsored by Bristol-Myers Squibb · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Melanoma by Bristol-Myers Squibb — 3 open to participants now, 9 under way, 3 of them phase 3. Melanoma · Bristol-Myers Squibb.

Enrollment
9th of 32
600 · median 366
Started
2015
with 9 others
Observational
32 of 111
none open now
Registered
81st of 111
by date

Among the 111 studies in Melanoma by Bristol-Myers Squibb, this one is the 9th largest by enrollment of the 32 observational ones that give a count, is one of 10 that started in 2015, is one of 32 observational ones, and was the 81st registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 111 studies in Melanoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Melanoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This study will review published trial literature and documents for Overall Survival (OS) to evaluate the association between the hazard of death and each baseline variable.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individual patient data (IPD) from the ipilimumab pooled analysis of clinical trials and observational studies will be used to construct the prognostic model for OS in advanced melanoma patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of melanoma

Exclusion criteria

Exclusion Criteria:

  • Age less than 18 years old
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (actual)
Patient registry
No

Groups and cohorts

  • First-Line Ipilimumab

    patients who received ipilimumab as their first-line treatment

    Other: Non-Interventional

Interventions

  • OtherNon-Interventional

    Non-Interventional

This study also gives Nivolumab, Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Prognostic Model of Overall Survival (OS)

    The OS prognostic model uses Individual patient data from a pooled analysis of 12 ipilimumab studies.

    Time frame: 10 years

07

Study locations

1 site
  • Local Institution
    Boston, Massachusetts 02199, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Dec 2017, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2018
First posted
Feb 19, 2018
StartActual
Jun 23, 2015
Primary completionActual
Dec 28, 2017
CompletionActual
Dec 28, 2017
Last update
Feb 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03438279
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Jun 23, 2015
Primary completion
Dec 28, 2017
Completion
Dec 28, 2017
Last update
Feb 19, 2018

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion